Abstract:Different biological subtype breast cancers respond differently to neoadjuvant chemotherapy, but it is unknown whether neoadjuvant or adjuvant chemotherapy leads to different long-term survival in each specific subtype although equal outcomes have been reported in general population. This study sought to clarify whether the selection of either neoadjuvant or adjuvant chemotherapy was linked to a differential survival benefit based on breast cancer subtypes. A prospectively maintained breast cancer database was queried from 2000 to 2008. All patients with a diagnosis of stage II and III breast cancer who received neoadjuvant or adjuvant chemotherapy were identified, only patients receiving docetaxel and epirubicin (TA) regimen were included. Patients were divided according to the administration of neoadjuvant or adjuvant chemotherapy. The biological subtypes were determined by immunohistochemical tests. The outcomes between neoadjuvant and adjuvant chemotherapy were compared in each different subtype. Kaplan-Meier curves were generated, and the Cox model was used to estimate the association between death risk and chemotherapy timing while adjusting for potentially confounding factors. P values < .05 were considered statistically significant. Of the 406 patients included, 201 (49.5%) received neoadjuvant chemotherapy, and 205 (50.5%) received an adjuvant TA regimen. Patients with the HER2+ and TNBC subtypes showed significantly higher pCR rates than patients with luminal types (P<.05). In general population, the neoadjuvant and adjuvant chemotherapy groups showed little survival variance (HR=1.15, 95% confidence interval (CI).691.91, P=.60). In luminal B-like patients, neoadjuvant chemotherapy led to worse overall survival (OS) than adjuvant therapy (HR=2.92, 95% CI 1.20 to 8.31, P=.02). In patients with the HER2+ subtype, neoadjuvant treatment corresponded to better OS(HR=.10, 95% CI.02-.58, P=.01). In contrast, patients with luminal A-like (HR=1.14, 95% CI.53-2.43, P=.74) and TNBC disease (HR=1.00, 95% CI.27-3.73, P=>.99) who underwent neoadjuvant chemotherapy showed equivalent OS when compared to patients undergoing adjuvant therapy. Neoadjuvant versus adjuvant chemotherapy results in a disparate impact on overall survival among patients with variant subtype breast cancer. When neoadjuvant chemotherapy was given, luminal B-like patients showed worse outcome, while patients with HER2+ disease had better OS. Prospective studies are necessary to determine and optimize the timing of chemotherapy for breast cancers with different molecular backgrounds.

Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database

Survival Benefit of Adjuvant Chemotherapy for Patients with Poorly Differentiated Stage IIA Colon Cancer

Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node-negative, human epidermal growth factor receptor 2-positive breast cancer: A Surveillance, Epidemiology, and End Results population-based study

The Impact of Neoadjuvant Chemotherapy on Patients With T1N0M0 Triple-Negative and HER-2 Positive Breast Cancer: A Retrospective Analysis Based on the SEER Database

Comparison of Surgeries Plus Perioperative and Postoperative Chemotherapies in Chinese Pn2 Patients with Non-Small Cell Lung Cancer: A Real-World Observational Study.

Outcomes Comparison Between Neoadjuvant Chemotherapy and Adjuvant Chemotherapy in Stage IIIA Non-Small Cell Lung Cancer Patients

Impacts of Tumor Stage at Diagnosis and Adjuvant Therapy on Long-Term Survival Outcomes in Patients with Triple-Negative Breast Cance Achieving Pathologic Complete Response After Neoadjuvant Chemotherapy

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy

Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based study

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?

Comparative effectiveness of neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stages IB2 to IIB of cervical cancer: a meta-analysis

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC

Adjuvant Chemotherapy in Pt2n0m0 Gastric Cancer: Findings from a Retrospective Study

Adjuvant chemotherapy and survival outcomes in older women with HR+/HER2- breast cancer: a propensity score-matched retrospective cohort study using the SEER database

Matched-case Comparison of Neoadjuvant Chemotherapy in Patients with FIGO Stage IB1-IIB Cervical Cancer to Establish Selection Criteria

Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC

Propensity-matched Analysis of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small-cell Lung Cancer Patients

Outcomes of Adjuvant Endocrine Therapy and Hormone Receptor Status Change Following Neoadjuvant Chemotherapy in Breast Cancer Patients.

Neoadjuvant Chemotherapy Followed by Surgery Versus Abdominal Radical Hysterectomy Alone for Oncological Outcomes of Stage IB3 Cervical Cancer—A Propensity Score Matching Analysis

Neoadjuvant Versus Adjuvant Chemotherapy with Taxanes and Anthracycline-Based Regimen: Which Leads to Better Outcome in Patients with Different Subtype Breast Cancer?